
Urticaria in Children: Diagnosis, Triggers & Treatment
All Things Urticaria – Learning about urticaria with Prof. Dr. Torsten ZuberbierShow Notes
In this episode, Prof. Torsten Zuberbier welcomes Dr. Larissa Brandão, pediatric allergist from the Federal University of São Paulo, Brazil, to talk about chronic urticaria in children — a condition that is often misunderstood and underdiagnosed.
They discuss: 🔹 When does chronic urticaria typically begin in kids? 🔹 What role do infections or allergens, play? 🔹 Which treatments are available in public healthcare? 🔹 How do cold urticaria and cholinergic urticaria show up in warm climates?
Dr. Brandão shares her clinical experience from Brazil, where many children with chronic urticaria also suffer from comorbidities like asthma and allergic rhinitis. She explains how treatment responses differ from adults and discusses the impact of restricted access to second-generation antihistamines. Join us for a practical and global look at what it takes to recognize, treat, and support children with chronic urticaria — especially in resource-limited settings.
Key Learnings from the Episode Chronic urticaria in children typically begins around age 7–8, with chronic spontaneous urticaria (CSU) being the most common subtype. In Brazil is the most common chronic inducible form; cold urticaria and cholinergic urticaria are also present but less frequent. Cold triggers in Brazil include ice cream, cold drinks, pools, and beaches — not ambient winter weather. Pediatric CSU patients often have comorbid atopic conditions, especially asthma and allergic rhinitis. Children tend to respond better than adults to standard or up-dosed second-generation antihistamines, but fatigue can be a common side effect. Loratadine is the only antihistamine widely available through Brazil’s public health system; desloratadine, bilastine, or fexofenadine are often unaffordable. Liver function monitoring is used for kids on high-dose loratadine. Omalizumab is rarely needed, but effective in more severe pediatric cases — especially those with comorbid asthma. Dupilumab is now licensed in Brazil for CSU in children aged 12+, and early reports show benefits for patients with both asthma and urticaria. Pseudoallergen-triggered symptoms (e.g. from candy, dyes, preservatives) are observed, and short-term elimination diets are used diagnostically. Cold urticaria can cause anaphylaxis, especially in pools — and adrenaline auto-injectors are recommended for high-risk children. Counseling on safety, including family education about temperature triggers, is essential for cold urticaria management. Brazilian UCARE centers use social media and in-clinic education to raise awareness and prepare for Urticaria Day (October 1) each year.
Chapters 00:00 Introduction to Urticaria in Children 01:46 Understanding Chronic Urticaria in Children 03:33 Infections and Chronic Urticaria 05:13 Allergic Comorbidities in Children 06:27 Treatment Algorithms for Chronic Urticaria 08:32 Dietary Influences on Urticaria 12:09 Cold Urticaria and Safety Concerns 15:13 Advancements in Urticaria Treatment 17:30 Advocacy and Awareness for Urticaria
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Feedback form: ATU: https://forms.office.com/e/m6a2uEdsUH
More from All Things Urticaria – Learning about urticaria with Prof. Dr. Torsten Zuberbier
In this episode of the UCARE Global Allergy and Asthma Excellence Network podcast on Urticaria, Prof. Torsten Zuberbier speaks with Prof. Angelo Valerio Marzano from Milan about urticarial vasculitis and its challenging differential diagnoses. They explore how clinicians can distinguish urticarial vasculitis from chronic urticaria and other dermatological or systemic conditions and discuss practical approaches to diagnosis and treatment.
In this episode of the Global Allergy and Asthma Excellence Network UCARE Podcast on Urticaria, Prof. Torsten Zuberbier speaks with Prof. Marta Ferrer from Spain about an important question: Is chronic spontaneous urticaria (CSU) only a skin disease, or is it a systemic inflammatory condition? Together, they discuss emerging evidence showing that urticaria affects far more than the skin and how this should influence patient management.
In this episode of the UCARE Global Allergy and Asthma Excellence Network (Global Allergy and Asthma Excellence Network) podcast on Urticaria, Prof. Torsten Zuberbier speaks with Prof. Akio Tanaka from Hiroshima University, Japan, about an important question many patients ask: how long will chronic urticaria last, and can treatment influence the course of the disease? They discuss disease modification, symptom control, and future research directions in urticaria management.
In this episode of the UCARE GA²LEN (Global Allergy and Asthma Excellence Network) podcast on Urticaria, Prof. Torsten Zuberbier and Prof. Hermenio Lima discuss the growing role of artificial intelligence (AI) in medicine and how it may influence urticaria care, research, and patient management in the future.
In this episode of the UCARE GA²LEN (Global Allergy and Asthma Excellence Network) podcast on Urticaria, Prof. Torsten Zuberbier and Prof. Maia Gotua discuss the role of infections in acute and chronic urticaria. They explore how infections can trigger, mimic, or worsen symptoms—and why careful clinical evaluation is key.